Idarubicin and High Dose Cytarabine: A New Salvage Treatment for Refractory or Relapsing Non-Hodgkin's Lymphoma-Reference-Cited by-同舟云学术

Idarubicin and High Dose Cytarabine: A New Salvage Treatment for Refractory or Relapsing Non-Hodgkin's Lymphoma

Published:1996-01 Issue:3-4 Volume:22 Page:329-334
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Dufour Patrick,Mors Ricardo,Berthaud Patrice,Lamy Thierry,Bergerat Jean-Pierre,Herbrecht Raoul,Maloisel Frederic,Audhuy Bruno,Lioure Bruno,Giron Cathy,Hurteloup Patrick,Oberling Francis

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.3109/10428199609051764

Reference17 articles.

1. Idarubicin

2. Phase II trial of idarubicin in patients with advanced lymphoma

3. Oral idarubicin in non-Hodgkin's lymphomas

4. High-dose cytosine arabinoside in non-Hodgkin's lymphoma.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Marine-Derived Anticancer Agents Targeting Apoptotic Pathways: Exploring the Depths for Novel Cancer Therapies;Marine Drugs;2024-02-28

2. Docosahexaenoic acid: A natural powerful adjuvant that improves efficacy for anticancer treatment with no adverse effects;BioFactors;2011-10-28

3. In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy;Leukemia Research;2009-01

4. Dietary Docosahexaenoic Acid Levels Influence the Outcome of Arabinosylcytosine Chemotherapy in L1210 Leukemic Mice;Nutrition and Cancer;2002-11

5. A Pharmacokinetic Study of Idarubicin in Japanese Patients With Malignant Lymphoma: Relationship With Leukocytopenia and Neutropenia;International Journal of Hematology;2001-10